ACSQHC-ARCR-244

Background: Durable mechanical circulatory support (dMCS) devices are an essential tool in the treatment of end-stage heart failure, used to prolong life and improve health so patients can be listed a heart transplant. These devices are only implanted in seven sites across Australia and New Zealand, and the numbers performed in each site are small. By joining sites' disparate information together, we can guide clinical practice and identify knowledge gaps. Aim: Collect clinical information on all patients in Australia and New Zealand who have end-stage heart failure and require durable mechanical circulatory support (dMCS) devices, and use this data to inform clinical practice and decision making. Study type: Prospective and retrospective observational longitudinal cohort study, a clinical quality improvement registry. Primary and secondary objectives: Identify and follow outcomes of patients who have a dMCS device implanted in Australia and New Zealand; Identify knowledge gaps for future research. Population: Approximately 75-90 patients a year. Inclusion criteria: Patients with a TGA-approved dMCS device (such as left ventricular assist devices, right ventricular assist devices, and total artificial hearts) implanted in Australia or New Zealand. Data collected: De-identified demographics, pre-implant cardiac, health, and QOL status, implant procedure, post-op stay, adverse events, follow-up, readmission, explant, transplant, and death details. Adverse events are infection, bleeding, neurological dysfunction, device malfunction, pump thrombus, haemolysis, right heart failure, renal dysfunction, and respiratory failure. The ANZMACS Registry contributes data to the International Mechanically Assisted Circulatory Support Registry (IMACS) run by the International Society for Heart and Lung Transplantation (ISHLT).